1461088011-0154bac9-18e1-4ed0-9c88-c910d14d870c

I claim:

1. An occluder apparatus for obstructing the flow of blood in a blood vessel comprising:
an elongated hollow tubular body having a leading end sized for reception in said blood vessel and including at least one portion of said body fabricated from a soluble material;
means for inserting said body through the wall of said blood vessel to extend said leading end into the interior of said blood vessel;
an inflatable diaphragm carried by said body in a collapsed, deflated condition;
means for conducting an inflating fluid from an external source into fluid communication with the interior of said diaphragm to effect expansion thereof; and
wherein said diaphragm in an inflated state is in flexible occluding engagement with the interior wall of said blood vessel about substantially the full circumference of a transverse section thereof.
2. The occluder apparatus according to claim 1, wherein said body includes means to enable release of said diaphragm.
3. The occluder apparatus according to claim 1, wherein said soluble material is soluble in a water-based medium.
4. The occluder apparatus according to claim 1, wherein said soluble material is soluble in blood.
5. The occluder apparatus according to claim 1, wherein said soluble material has solubility characteristics, such that a temperature solubility curve is intersected at a temperature in a range of about 1 to 41 C. and a dissolution time in a range of about 5 seconds to 30 minutes.
6. The occluder apparatus according to claim 1, wherein said soluble material is organic.
7. The occluder apparatus according to claim 5, wherein said soluble organic material is selected from the group consisting of carbohydrates, proteins, gelatins, plastics, lipids and lipid compounds, and polyethyl glycol.
8. The occluder apparatus according to claim 1, wherein said soluble material is inorganic.
9. The occluder apparatus according to claim 7, wherein said soluble inorganic material is selected from the group consisting of sodium chloride and sodium bicarbonate.
10. The occlude apparatus according to claim 1, wherein said soluble material includes a plurality of soluble layers, each of said plurality of layers having solubility characteristics different from at least another of said plurality of layers.
11. The occluder apparatus according to claim 1, wherein said soluble material includes a honeycomb structure and a honeycomb filling material, such that said honeycomb structure and said honeycomb filling material have different solubility characteristics.
12. The occluder apparatus according to claim 1, wherein said body includes a honeycomb portion and said at least one soluble portion is a honeycomb filling portion.
13. The occluder apparatus according to claim 2, in which said diaphragm release-enabling means comprises elongated openings extending longitudinally of said body.
14. The occluder apparatus according to claim 13, in which said openings for releasing said diaphragm are substantially oppositely disposed in lateral alignment for releasing said diaphragm upon inflation substantially coincidently through both of said openings.
15. The occluder apparatus according to claim 13, including means forming a partition extending transversely of the interior of said body defining longitudinal fluid-conducting passage means therein; and means forming at least one fluid opening in the wall of said body to place said passage means in fluid communication with the exterior of said body.
16. The occluder apparatus according to claim 1, in which said diaphragm, when inflated, defines a generally toroidally-shaped cushion portion for engaging the interior wall of said blood vessel about substantially the full circumference thereof and has a membrane portion filling the region interior of said cushion portion.
17. The occluder apparatus according to claim 1, including means on the exterior of said body for securing said body with respect to said blood vessel.
18. The occluder apparatus according to claim 17, in which said securing means comprises laterally disposed flange means extending from the exterior of said body, said flange means providing means for attaching said body to the wall of said blood vessel via sutures.
19. The occluder apparatus according to claim 1, including piercing means at the leading end of said body for incising the wall of said blood vessel to effect penetration of said blood vessel wall by said body.
20. The occluder apparatus according to claim 19, wherein said piercing means is fabricated from a soluble material.
21. The occluder apparatus according to claim 19, in which said piercing means are removably attached to said body to enable their withdrawal from said body following penetration of said vessel wall and prior to inflation of said diaphragm.
22. The occluder apparatus according to claim 19, in which said piercing means comprises a generally conical plug carried by the leading end of said body, the apex of said plug forming a point to effect penetration of the wall of said blood vessel.
23. The occluder apparatus according to claim 20, in which said piercing means comprises a hollow plug formed of expandable material, which, in an expanded condition, defines a generally conical exterior shape the apex of which forms a point to effect penetration of the wall of said blood vessel, and means forming a passage extending through said body to communicate the interior of said plug with an external source of inflating fluid, whereby said plug is expandable by said inflating fluid into a piercing configuration or collapsible into a condition for removal from said body.
24. The occluder apparatus according to claim 15, in which said fluid passage means includes means at an end opposite said wall openings connecting said passage means with at least one fluid source exteriorly of said body.
25. The occluder apparatus according to claim 24, in which said passage means connects at said end with a source of myocardial fluid for supply said fluid to said blood vessel on a proximate side of said diaphragm.
26. The occluder apparatus according to claim 24, in which said passage means connects at said end with a pressure monitor for monitoring the internal pressure of said blood vessel on a side of said diaphragm.
27. The occluder apparatus according to claim 24, in which said passage means connects at said end with heart-lung machine for circulating blood to said blood vessel on a side of said diaphragm.
28. The occluder apparatus according to claim 24, including means for separately connecting said one end of said fluid passage means to both a source of myocardial fluid and to a pressure monitor; and valve means for connecting said fluid passage means with said myocardial fluid and said pressure monitor.
29. The occluder apparatus according to claim 28, including valve means in said passage means for selectively admitting blood supply from said heart-lung machine to said passage means.
30. The occluder apparatus according to claim 24, in which said partition means comprises a partition plate extending chordally across the interior of said tubular body to divide said interior into parallel longitudinally-extending fluid-conducting passages; a first in said body for fluidly communicating one of said passages with said blood vessel on the proximal side of said diaphragm and a second opening in said body on the other side of said diaphragm release-enabling means for fluidly connecting the other of said passages with said blood vessel on the distal side of said diaphragm.
31. The occluder apparatus according to claim 30, including means at an end of said one passage for connecting said one passage to a source of myocardial fluid for circulation through said first opening with said blood vessel on the proximal side of said diaphragm.
32. The occluder apparatus according to claim 30, including means at an end of said one passage for connecting said one passage to a pressure monitor for monitoring the internal pressure of said blood vessel on the proximal side of said diaphragm.
33. The occluder apparatus according to claim 30, including means at an end of said one passage for connecting said one passage to a source of myocardial fluid and to a pressure monitor, and valve means operable with said connecting means for connecting said passage to said source of myocardial fluid and to said pressure monitor.
34. The occluder apparatus according to claim 30, including means at an end of said other passage for connecting said other passage to a heart-lung machine to circulate blood from said heart-lung machine to said blood vessel on the distal side of said diaphragm.
35. The occluder apparatus according to claim 34, including valve means in said other passage for selectively circulating blood from said heart-lung machine to said blood vessel on the distal side of said diaphragm.
36. The occluder apparatus according to claim 32, including means at an end of said other passage for connecting said other passage to a heart-lung machine; and the valve means in said other passage for selectively circulating blood from said heart-lung machine to said blood vessel on the distal side of said diaphragm.
37. An occluder apparatus for obstructing the flow of blood in a blood vessel comprising, in combination:
an elongated hollow tubular body having a leading end for reception in said blood vessel and including at least one portion of said body fabricated from a soluble material;
means for inserting said body through the wall of said blood vessel to extend said leading end into the interior of said blood vessel;
an inflatable diaphragm carried by said body in a collapsed, deflated condition for insertion into the interior of said blood vessel;
means for inflating said diaphragm to expand it about its periphery into cushioned occluding engagement with the interior wall of said blood vessel;
a belt-like pressurizing device including an inflatable cuff arranged to substantially surround the exterior of said blood vessel and to be expanded under the influence of fluid pressure into engagement with the exterior wall thereof in substantially opposing relation to the engagement of said interior wall of said blood vessel by said diaphragm; and
means for inflating said cuff.
38. The combination according to claim 37, in which said diaphragm-inflating means and said cuff-inflating means are fluidly interconnected for the admission of pressurizing fluid for the substantial simultaneous inflating of said diaphragm and said cuff.
39. The combination according to claim 38, in which said belt-like pressurizing device comprises:
a base adapted to enclose the exterior of said blood vessel;
means for attaching said cuff to the wall-facing surface of said base;
inflating-fluid inlet means formed on said base in fluid communication with the interior of said cuff for supplying pressurizing fluid thereto; and
means on said base retaining said body.
40. The combination according to claim 39, in which said retaining means comprises a substantially annular collar extending from the exterior surface of said base; and means forming an opening extending through said collar and said cuff to receive said body.
41. The combination according to claim 40, including at least one locking projection extending from said body; and means on said collar cooperable with said projection for fixedly retaining said body.
42. The combination according to claim 41, including means on the exterior of said body for receiving sutures to fix said body to said blood vessel; and said locking projection on said body engaging a cooperating recess in said collar when said belt is superimposed on said body.
43. The combination according to claim 42, including a bayonet slot formed on the interior surface of said collar, said bayonet slot cooperating with said locking projection upon applying said tubular body to said collar for locking said body with respect to said collar.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A speaker system comprising a housing and a linear array of a plurality of sound-generating transducers, said housing comprising a cylinder having a longitudinal axis and substantially circular cross-section, said linear array of sound-generating transducers being mounted upon a substantially planar chord configured within a side wall of said cylinder.
2. The speaker system of claim 1 wherein said planar chord is characterized as having a longitudinal axis being substantially parallel to the longitudinal axis of said cylinder.
3. The speaker system of claim 1 wherein said planar chord is characterized as having a longitudinal axis inclined with respect to the longitudinal axis of said cylinder.
4. The speaker system of claim 1 wherein said sound generating transducers comprise a line array of mid-range frequency transducers.
5. The speaker system of claim 4 wherein said sound generating transducers further comprise a line array of high-frequency transducers.
6. The speaker system of claim 5 wherein said line array of mid-range frequency transducers and said line array of high-frequency transducers are both mounted upon said substantially planar chord.
7. The speaker system of claim 5 wherein said line array of mid-range frequency transducers are mounted upon said substantially planar chord and said linear array of high-frequency transducers are mounted upon a second housing said second housing having a longitudinal axis substantially parallel to the longitudinal axis of said cylinder.
8. The speaker system of claim 7 wherein said housing for said linear array of mid-range frequency transducers and said housing for said linear array of high-frequency transducers are mounted upon a common base.
9. The speaker system of claim 8 wherein the longitudinal axis of said cylinder and longitudinal axis of said second housing extend substantially vertically from said common base.
10. The speaker system of claim 7 wherein said second housing comprises a solid cylindrical rod having cut out portions to receive and fixedly support said line array of high-frequency transducers.
11. The speaker system of claim 1 wherein said housing is characterized as having a substantially concave interior wall and mounted upon said concave interior wall diametrically opposite said substantially planar chord is a sound wave diffuser.
12. The speaker system of claim 11 wherein said sound wave diffuser comprises a bisector.
13. The speaker system of claim 11 wherein said sound wave diffuser comprises a convex surface extending substantially the length of said linear array of sound generating transducers.
14. The speaker system of claim 11 wherein said sound wave diffuser comprises a series of L-shaped angle irons extending substantially the length of said linear array of sound generating transducers.
15. The speaker system of claim 1 wherein each of said sound-generating transducers are positioned as close as possible to one another is creating said linear array.
16. The speaker system of claim 4 wherein said linear array of mid-range frequency transducers and linear array of high-frequency transducers are substantially parallel to one another.
17. The speaker system of claim 16 wherein the spacing interval between individual high-frequency transducers along said line array of high-frequency transducers is not integrally related to the spacing interval between individual mid-range frequency transducers along said line array of mid-range frequency transducers.
18. An audio-video display system comprising a video display screen and a series of at least three linear array sets of sound-generating transducers, each linear array set comprising a plurality of mid-range frequency transducers and high-frequency transducers, said mid-range frequency transducers of each set extending along a line substantially parallel to a line of said high-frequency transducers of the same set wherein a first and second of said linear arrays being positioned vertically to the left and right of said video display screen, respectively, and a third of said linear arrays being horizontally positioned below said video display screen.
19. The audio-video display system of claim 18 wherein said video display screen is mounted upon a vertically extending structural wall.
20. The audio-video display system of claim 19 wherein said at least three linear array sets of sound-generating transducers are positioned upon said vertically extending structural wall.
21. The audio-video display system of claim 20 wherein said at least three linear array sets of sound-generating transducers are flush mounted to said vertically extending structural wall.
22. The audio-video display system of claim 18 wherein each linear array set of sound-generating transducers is supported by a housing.
23. The audio-video display system of claim 22 wherein each housing is substantially cylindrical with a substantially planar chord configured within a side wall of said cylindrical housing for supporting said sound-generating transducers.
24. The audio-video display of claim 22 wherein sets of linear arrays of mid-range frequency transducers and high-frequency transducers are contained within separate housings.
25. The audio-video display of claim 18 wherein said video display screen is substantially rectangular having a length and height and wherein said vertically extending linear arrays are of approximate dimension of said height and said horizontally extending linear array is of an approximate dimension of said width of said video display screen.
26. A loudspeaker system positioned within millwork of a residential or commercial environment having an aperture therein, said positioning of said loudspeaker system within said millwork being such as to visually obscure the loudspeaker system, said loudspeaker system comprising linear arrays of sound-generating transducers, said linear arrays comprising a plurality of mid-range frequency transducers and high-frequency transducers, said sound generating transducers being positioned so that at least a portion of acoustic energy emanated from said transducers passes through said aperture.
27. A room audio speaker, said room comprising at least one vertical wall, a horizontally extending ceiling forming an aperture there between and operative between said wall and ceiling and linear arrays of sound-generating transducers, said linear arrays comprising a plurality of mid-range frequency transducers and high-frequency transducers, said sound-generating transducers being positioned so that at least a portion of acoustic energy emanating from said transducers passes through said aperture and into said room.

1461088001-f9a53960-b866-407e-87bc-691e11caf067

1. A system for sensing soot of a diesel engine, comprising: a combustion element including a porous ceramic structure to which a catalytic substance that combustion-reacts with the soot is fixed; a comparison element including the porous ceramic structure to which a stable substance that does not combustion-react with the soot is fixed; and
a detection section for detecting the temperatures of the combustion element and the comparison element and for deducing the soot formation amount among exhaust gas by using the temperature difference of the respective element.
2. The system for sensing soot of a diesel engine of claim 1, wherein the ceramic structure comprises Al2O3.
3. The system for sensing soot of a diesel engine of claim 1, wherein the ceramic structure comprises SiO2.
4. The system for sensing soot of a diesel engine of claim 1, wherein the stable substance consists mainly of TiO2.
5. The system for sensing soot of a diesel engine of claim 1, wherein the catalytic substance uses TiO2 as a support and consists of a fixed element that is combustion-reacted with the soot.
6. The system for sensing soot of a diesel engine of claim 1, further comprising a heating section for heating the combustion element so that the catalytic substance is combustion-reacted with the soot among exhaust gas.
7. The system for sensing soot of a diesel engine of claim 6, wherein the heating section heats equally the combustion element and the comparison element.
8. The system for sensing soot of a diesel engine of claim 1, wherein the detection section deduces the soot formation amount among exhaust gas by converting the temperature difference produced between the combustion element and the comparison element into electric signal.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A process for producing high purity (S)-2-4-(3-fluorobenzyloxy)benzylaminopropanamide (safinamide) or (S)-2-4-(2-fluorobenzyloxy)benzylaminopropanamide (ralfinamide) of formula (Ia) or (Ib)
and pharmaceutically acceptable acid salts thereof, comprising:
submitting a Schiff base intermediate respectively of formula (VIa) or (VIb)
to catalytic hydrogenation with hydrogen gas in the presence of a heterogeneous catalyst in a protic organic solvent and, when safinamide or ralfinamide are obtained in a free base form, optionally converting said free base form to a salt thereof with a pharmaceutically acceptable acid.
2. The process as in claim 1 wherein the catalytic hydrogenation is carried out by using an heterogeneous catalyst selected from nickel, rhodium, platinum and palladium catalysts on an inert support in the presence of a solvent selected from lower aliphatic (C1-C5) alkanols.
3. The process as in claim 1 wherein the catalyst is a palladium or platinum catalyst.
4. The process as in claim 1 wherein the catalyst is wet 5% PtC (50% H2O) or wet 10% PdC (50% H2O).
5. The process as in claim 1 wherein the pharmaceutically acceptable acid is methanesulfonic acid.
6. The process as in claim 1 wherein the hydrogen pressure is between 1 and 10 bars and the temperature is between 10\xb0 C. and 70\xb0 C.
7. The process as in claim 6 wherein the hydrogen pressure is between 3 and 6 bars and the temperature is between 25\xb0 C. and 40\xb0 C.
8. The process as in claim 1 wherein the catalytic hydrogenation is carried out on a Schiff base intermediate (VIa) or (VIb) which has been prepared through iminoalkylation of 4-(3-fluorobenzyloxy)benzaldehyde (IVa) or 4-(2-fluorobenzyloxy)benzaldehyde (IVb)
with L-alaninamide in the presence of a protic organic solvent.
9. The process as in claim 8 wherein the L-alaninamide is employed as an acid addition salt thereof in the presence of a base in an amount sufficient to set free L-alaninamide from its salt.
10. The process as in claim 8 where the catalytic hydrogenation of the Schiff base intermediate is performed on the same reaction mixture resulting from the completion of the iminoalkylation reaction under conditions which provoke the precipitation of said Schiff base intermediate to obtain a suspension of said intermediate in the same reaction solvent.
11. The process as in claim 8 wherein the Schiff base intermediate resulting from the completion of the iminoalkylation reaction is isolated before undergoing the catalytic hydrogenation step.
12. The process as in claim 8 wherein the 4-(3-fluorobenzyloxy)benzaldehyde or 4-(2-fluorobenzyloxy)benzaldehyde of formula (IVa) or (IVb) employed as the starting material to obtain the Schiff base intermediate of formula (VIa) or (VIb) contains less than 0.03% (by weight), of the respective impurities 3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)benzaldehyde (Va) or 3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)benzaldehyde (Vb)
13. The process according to claim 12 wherein the 4-(3-fluorobenzyloxy)benzaldehyde (IVa) or 4-(2-fluorobezyloxy)benzaldehyde (IVb) is obtained by alkylation of 4-hydroxybenzaldehyde with, respectively, a 3-fluorobenzyl or 2-fluorobenzyl derivative (IIIa) or (IIIb)
where Y is a leaving group selected from Cl, Br, I, OSO2CH3 and OSO2\u2014C6H4-pCH3, in the presence of a base, and is submitted to crystallization before the use in the successive reaction step.
14. The process as in claim 13 wherein Y is Cl.
15. The process as in claim 13 or 14 wherein the crystallization is carried out by adding an inert organic non-solvent to a solution of the 4-(3-fluorobenzyloxy)benzaldehyde (IVa) or 4-(2-fluorobenzyloxy)benzaldehyde (IVb) in an inert organic solvent.
16. The process as in claim 15 wherein the inert organic non-solvent is selected from lower aliphatic hydrocarbons and the inert organic solvent is selected from aromatic hydrocarbons.
17. The process as in claim 16 wherein the lower aliphatic hydrocarbon is n-hexane and the aromatic hydrocarbon is toluene.
18. The process as in any of claims 13 and 14 wherein the crystallization is carried out by dissolving the 4-(3-fluorobenzyloxy)benzaldehyde (IVa) or 4-(2-fluorobenzyloxy)benzaldehyde (IVb) in a hot solvent selected from cyclohexane, and a di(C3-C4)alkyl ether at reflux, and then cooling the solution to a temperature at or below room temperature.
19. The process as in any of claims 13 and 14 wherein the alkylation reaction is carried out under phase transfer conditions.
20. The process as in claim 19 wherein the alkylation under phase transfer condition is performed in a solidliquid system wherein the reagents and the phase transfer catalyst are dissolved in a liquid organic phase and the solid phase is constituted by an inorganic base or a salt of 4-hydroxy benzaldehyde with said inorganic base.
21. The process as in claim 19 wherein the alkylation under phase transfer conditions is performed in a liquidliquid system wherein the alkylating reagent 3-fluorobenzyl or 2-fluorobenzyl derivative of formula (IIIa) or (IIIb) is dissolved in a liquid organic phase and the 4-hydroxybenzaldehyde is dissolved in an aqueous phase as a salt with an inorganic base.
22. The process as in claim 19 wherein the phase transfer catalyst is selected from quaternary ammonium or phosphonium salts or polyethyleneglycols of low molecular weight.
23. The process of claim 22 wherein the amount of phase transfer catalyst employed is between 0.02 to 1 mole per mole of 4-hydroxybenzaldheyde.
24. The process as in claim 23 wherein the amount of phase-transfer catalyst is 0.1 to 1 mole per mole of 4-hydroxybenzaldehyde.
25. The process as in claim 20 wherein the organic solvent of the liquid organic phase is selected from dialkyl ethers and aromatic hydrocarbons.
26. The process as in claim 21 wherein the molar ratio between the alkylating reagent of formula (IIIa) or (IIIb), and 4-hydroxybenzaldehyde is between 0.6 and 1.5.
27. The process as in claim 20 wherein the temperature is between 60\xb0 C. and 160\xb0 C.
28. The process as in claim 20 wherein the inorganic base is selected from Na2CO3, K2CO3, NaOH and KOH, the temperature is between 80\xb0 C. and 120\xb0 C., and the ratio between the alkylating reagent of formula (IIIa) or (IIIb), and 4-hydroxybenzaldehyde is between 0.9 and 1.1.
29. The process as in claim 12 wherein safinamide or ralfinamide or their pharmaceutically acceptable acid salts, have a content of the respective impurity (S)-2-3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylaminopropanamide (IIa) or (S)-2-3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylaminopropanarnide (IIb)
or their pharmaceutically acceptable acid salts, which is lower than 0.03% (by weight).
30. The process as in claim 29 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight).
31. An isolated Schiff base of formula (VIa) or (VIb)
32. High purity safinamide or ralfinamide or a pharmaceutically acceptable acid salt thereof with a content of the respective impurity (S)-2-3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylaminopropanamide (IIa) or (S)-2-3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylaminopropanamide (IIb)
or their pharmaceutically acceptable acid salts, which is lower than 0.03% (by weight).
33. High purity safinamide or ralfinamide salt with a pharmaceutically acceptable acid as in claim 32 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight).
34. A pharmaceutical formulation containing high purity safinamide or ralfinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the respective impurity of formula (IIa) or (IIb) of claim 32 or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).
35. The pharmaceutical formulation of claim 34 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight).
36. The pharmaceutical formulation of claim 34, further comprising one or more additional active agent(s) in addition to high purity degree safinamide or ralfinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the respective impurity (S)-2-3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)-benzylaminopropanamide (IIa) or (S)-2-3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylaminopropanamide (IIb) or a salt thereof is lower than 0.03% (by weight).
37. The pharmaceutical formulation of claim 36 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) or (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight).
38. The pharmaceutical formulation containing high purity safinamide or a salt thereof with a pharmaceutically acceptable acid according to any of claims 36 and 37 wherein the additional active agent is at least one of a dopamine agonist, levodopa, or a catechol-O-methyltransferase (COMT) inhibitor.
39. The pharmaceutical formulation containing high purity ralfinamide or a pharmaceutically acceptable acid salt thereof according to any of claims 36 and 37 wherein the additional active agent is gabapentin or pregabalin, or a pharmaceutically acceptable acid addition salt thereof.
40. A method for treating CNS disorders, selected from the group consisting of epilepsy, Parkinson disease, Alzheimer disease, depression, restless legs syndrome and migraine comprising administering to a patient in need thereof an effective amount of high purity safinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the impurity (S)-2-3-(3-fluorobenzyloxy)-4-(3-fluorobenzyl)-benzylaminopropanamide of formula (IIa)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).
41. The method of claim 40, wherein the disorder is Parkinson’s disease or restless legs syndrome which comprises administering to a patient in need of said treatment an effective amount of high purity safinamide or a pharmaceutically acceptable acid salt thereof wherein the content of the impurity of formula (IIa) or a salt thereof with a pharmaceutically acceptable acid is lower than 0.03% (by weight), optionally in conjunction with one or more Parkinson’s disease active agent(s).
42. The method of claim 41 wherein the Parkinson’s disease active agent is at least one of a dopamine agonist, levodopa, or a catechol-O-methyltransferase (COMT) inhibitor.
43. The method as in any of claims 40 to 42 wherein the pharmaceutically acceptable acid is methanesulfonic acid and the content of the respective impurity of formula (IIa) as the salt with methanesulfonic acid is lower than 0.01% (by weight).
44. The method as in claim 40 wherein the patient in need of the treatment is classified as poor metabolizer (PM) or is concomitantly consuming other drugs which are known to interact with the cytochromes of the CYP450 system or are known to have HERG channel blocking properties.
45. A method for treating pain conditions, migraine, bipolar disorders, depressions, cardiovascular, inflammatory, urogenital, metabolic and gastrointestinal disorders comprising administering to a patient in need thereof an effective amount of high purity ralfinamide or a salt thereof with a pharmaceutically acceptable acid wherein the content of the impurity 2-3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylaminopropanamide of formula (IIb)
or a pharmaceutically acceptable acid salt thereof is lower than 0.03% (by weight).
46. The method as in claim 45 for treating pain conditions and migraine, optionally in conjunction with gabapentin or pregabalin, or a pharmaceutically acceptable acid addition salt thereof.
47. The method as in any of claims 45 and 46 wherein the salt of ralfinamide with a pharmaceutically acceptable acid is a salt with methanesulfonic acid and the content of the respective impurity of formula (IIb) as the salt with methanesulfonic acid is lower than 0.01% (by weight).
48. The method as in claim 45 wherein the patient in need of the treatment is classified as poor metabolizer (PM) or is concomitantly consuming other drugs which are known to interact with the cytochromes of the CYP450 system or are known to have HERG channel blocking properties.
49. The method as in any of claims 45 and 48 wherein the patient is affected by a bipolar disorder.
50. The method as in claim 49 wherein the salt of ralfinamide with a pharmaceutically acceptable acid which is administered to the patent affected by a bipolar disorder is the salt with methanesulfonic acid.
51. The process as in claim 2 wherein the lower aliphatic (C1-C5) alkanol is methanol, ethanol, or isopropanol.
52. The process as in claim 3 wherein the catalyst is platinum.
53. The process as in claim 4 wherein the catalyst is wet 5% PtC (50% H2O).
54. The process as in claim 12 wherein the 4-(3-fluorobenzyloxy)benzaldehyde or 4-(2-fluorobenzyloxy)benzaldehyde of formula (IVa) or (IVb) employed as the starting material to obtain the Schiff base intermediate of formula (VIa) or (VIb) contains less than 0.01% (by weight), of the respective impurities 3-(3-fluorobenzyl)-4-(3-fluorobenzyloxy)benzaldehyde (Va) or 3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)benzaldehyde (Vb).
55. The process as in claim 18 wherein the hot solvent is diisopropylether.
56. The process as in claim 18 wherein the temperature is about 10-15\xb0 C.
57. The method as in claim 45 wherein the content of the impurity 2-3-(2-fluorobenzyl)-4-(2-fluorobenzyloxy)-benzylaminopropanamide of formula (IIb) or a pharmaceutically acceptable acid salt thereof is lower than 0.01% (by weight).
58. The method as in claim 45 or 46 wherein the pain condition is chronic pain or neuropathic pain.